The General Hospital Corporation

Dana-Farber-Cancer Institute Inc.

Cold Spring Harbor Laboratory

Wyeth

Rutgers, the State University of New Jersey

Raffaella Sordella

Daniel Arie Haber

Jeffrey E Settleman

Daphne Winifred Bell

Pasi Antero Janne

Matthew Meyerson

Thomas J Lynch

William R Sellers

Juan Guillermo Paez

Bruce E Johnson

Bruce E Johnston

Sridhar Krishna Rabindran

Nadia G Godin-Heymann

Trine Lindsted

Eunice L Kwak

Silvia Fenoglio

Serif Senturk

Luca Cartegni

Zhan Yao

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

Method for treating gefitinib resistant cancer

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.

Provided herein are methods and compositions for inhibiting epithelial to mesenchymal transition of a cell.

Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (EMT) in cancer cells

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Cancer treatment with a combination of an Epidermal Growth Factor Receptor tyrosine kinase inhibitor and an Interleukin-6 inhibitor.

Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors

Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers

Growing community of inventors

Bedford, MA, United States of America

Raffaella Sordella